ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hepatitis Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-12X11393
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Hepatitis Drugs Market Research Report 2022
BUY CHAPTERS

Global Hepatitis Drugs Market Research Report 2025

Code: QYRE-Auto-12X11393
Report
September 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
F.Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline PLC
Johnson & Johnson
Merck
Novartis
Vertex Pharmaceuticals
AbbVie
Achillion Pharmaceuticals
Bristol–Myers Squibb

Hepatitis Drugs Market Size

The global market for Hepatitis Drugs was valued at US$ 106240 million in the year 2024 and is projected to reach a revised size of US$ 464410 million by 2031, growing at a CAGR of 23.8% during the forecast period.

Hepatitis Drugs Market

Hepatitis Drugs Market

Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Hepatitis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis Drugs.
The Hepatitis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hepatitis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Hepatitis Drugs Market Report

Report Metric Details
Report Name Hepatitis Drugs Market
Accounted market size in year US$ 106240 million
Forecasted market size in 2031 US$ 464410 million
CAGR 23.8%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • VEMLIDY
  • EPCLUSA
  • SOVALDI
  • INCIVEK
  • OLYSIO
  • VICTRELIS
  • VIREAD
  • HEPSERA
  • BARACLUDE
  • TYZEKA
Segment by Application
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Hepatitis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Hepatitis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Hepatitis Drugs Market growing?

Ans: The Hepatitis Drugs Market witnessing a CAGR of 23.8% during the forecast period 2025-2031.

What is the Hepatitis Drugs Market size in 2031?

Ans: The Hepatitis Drugs Market size in 2031 will be US$ 464410 million.

Who are the main players in the Hepatitis Drugs Market report?

Ans: The main players in the Hepatitis Drugs Market are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb

What are the Application segmentation covered in the Hepatitis Drugs Market report?

Ans: The Applications covered in the Hepatitis Drugs Market report are Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E

What are the Type segmentation covered in the Hepatitis Drugs Market report?

Ans: The Types covered in the Hepatitis Drugs Market report are VEMLIDY, EPCLUSA, SOVALDI, INCIVEK, OLYSIO, VICTRELIS, VIREAD, HEPSERA, BARACLUDE, TYZEKA

1 Hepatitis Drugs Market Overview
1.1 Product Definition
1.2 Hepatitis Drugs by Type
1.2.1 Global Hepatitis Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 VEMLIDY
1.2.3 EPCLUSA
1.2.4 SOVALDI
1.2.5 INCIVEK
1.2.6 OLYSIO
1.2.7 VICTRELIS
1.2.8 VIREAD
1.2.9 HEPSERA
1.2.10 BARACLUDE
1.3 Hepatitis Drugs by Application
1.3.1 Global Hepatitis Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hepatitis A
1.3.3 Hepatitis B
1.3.4 Hepatitis C
1.3.5 Hepatitis D
1.3.6 Hepatitis E
1.4 Global Hepatitis Drugs Market Size Estimates and Forecasts
1.4.1 Global Hepatitis Drugs Revenue 2020-2031
1.4.2 Global Hepatitis Drugs Sales 2020-2031
1.4.3 Global Hepatitis Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Hepatitis Drugs Market Competition by Manufacturers
2.1 Global Hepatitis Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Hepatitis Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Hepatitis Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Hepatitis Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hepatitis Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hepatitis Drugs, Product Type & Application
2.7 Global Key Manufacturers of Hepatitis Drugs, Date of Enter into This Industry
2.8 Global Hepatitis Drugs Market Competitive Situation and Trends
2.8.1 Global Hepatitis Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Hepatitis Drugs Players Market Share by Revenue
2.8.3 Global Hepatitis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hepatitis Drugs Market Scenario by Region
3.1 Global Hepatitis Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Hepatitis Drugs Sales by Region: 2020-2031
3.2.1 Global Hepatitis Drugs Sales by Region: 2020-2025
3.2.2 Global Hepatitis Drugs Sales by Region: 2026-2031
3.3 Global Hepatitis Drugs Revenue by Region: 2020-2031
3.3.1 Global Hepatitis Drugs Revenue by Region: 2020-2025
3.3.2 Global Hepatitis Drugs Revenue by Region: 2026-2031
3.4 North America Hepatitis Drugs Market Facts & Figures by Country
3.4.1 North America Hepatitis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Hepatitis Drugs Sales by Country (2020-2031)
3.4.3 North America Hepatitis Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hepatitis Drugs Market Facts & Figures by Country
3.5.1 Europe Hepatitis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Hepatitis Drugs Sales by Country (2020-2031)
3.5.3 Europe Hepatitis Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hepatitis Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Hepatitis Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Hepatitis Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Hepatitis Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hepatitis Drugs Market Facts & Figures by Country
3.7.1 Latin America Hepatitis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Hepatitis Drugs Sales by Country (2020-2031)
3.7.3 Latin America Hepatitis Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hepatitis Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Hepatitis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Hepatitis Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Hepatitis Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hepatitis Drugs Sales by Type (2020-2031)
4.1.1 Global Hepatitis Drugs Sales by Type (2020-2025)
4.1.2 Global Hepatitis Drugs Sales by Type (2026-2031)
4.1.3 Global Hepatitis Drugs Sales Market Share by Type (2020-2031)
4.2 Global Hepatitis Drugs Revenue by Type (2020-2031)
4.2.1 Global Hepatitis Drugs Revenue by Type (2020-2025)
4.2.2 Global Hepatitis Drugs Revenue by Type (2026-2031)
4.2.3 Global Hepatitis Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Hepatitis Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Hepatitis Drugs Sales by Application (2020-2031)
5.1.1 Global Hepatitis Drugs Sales by Application (2020-2025)
5.1.2 Global Hepatitis Drugs Sales by Application (2026-2031)
5.1.3 Global Hepatitis Drugs Sales Market Share by Application (2020-2031)
5.2 Global Hepatitis Drugs Revenue by Application (2020-2031)
5.2.1 Global Hepatitis Drugs Revenue by Application (2020-2025)
5.2.2 Global Hepatitis Drugs Revenue by Application (2026-2031)
5.2.3 Global Hepatitis Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Hepatitis Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche
6.1.1 F. Hoffmann-La Roche Company Information
6.1.2 F. Hoffmann-La Roche Description and Business Overview
6.1.3 F. Hoffmann-La Roche Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 F. Hoffmann-La Roche Hepatitis Drugs Product Portfolio
6.1.5 F. Hoffmann-La Roche Recent Developments/Updates
6.2 Gilead Sciences
6.2.1 Gilead Sciences Company Information
6.2.2 Gilead Sciences Description and Business Overview
6.2.3 Gilead Sciences Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Gilead Sciences Hepatitis Drugs Product Portfolio
6.2.5 Gilead Sciences Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Company Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Hepatitis Drugs Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Company Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Johnson & Johnson Hepatitis Drugs Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
6.5 Merck
6.5.1 Merck Company Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merck Hepatitis Drugs Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Company Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis Hepatitis Drugs Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Vertex Pharmaceuticals
6.7.1 Vertex Pharmaceuticals Company Information
6.7.2 Vertex Pharmaceuticals Description and Business Overview
6.7.3 Vertex Pharmaceuticals Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Vertex Pharmaceuticals Hepatitis Drugs Product Portfolio
6.7.5 Vertex Pharmaceuticals Recent Developments/Updates
6.8 Abbvie
6.8.1 Abbvie Company Information
6.8.2 Abbvie Description and Business Overview
6.8.3 Abbvie Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Abbvie Hepatitis Drugs Product Portfolio
6.8.5 Abbvie Recent Developments/Updates
6.9 Achillion Pharmaceuticals
6.9.1 Achillion Pharmaceuticals Company Information
6.9.2 Achillion Pharmaceuticals Description and Business Overview
6.9.3 Achillion Pharmaceuticals Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Achillion Pharmaceuticals Hepatitis Drugs Product Portfolio
6.9.5 Achillion Pharmaceuticals Recent Developments/Updates
6.10 Bristol-Myers Squibb
6.10.1 Bristol-Myers Squibb Company Information
6.10.2 Bristol-Myers Squibb Description and Business Overview
6.10.3 Bristol-Myers Squibb Hepatitis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bristol-Myers Squibb Hepatitis Drugs Product Portfolio
6.10.5 Bristol-Myers Squibb Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hepatitis Drugs Industry Chain Analysis
7.2 Hepatitis Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hepatitis Drugs Production Mode & Process Analysis
7.4 Hepatitis Drugs Sales and Marketing
7.4.1 Hepatitis Drugs Sales Channels
7.4.2 Hepatitis Drugs Distributors
7.5 Hepatitis Drugs Customer Analysis
8 Hepatitis Drugs Market Dynamics
8.1 Hepatitis Drugs Industry Trends
8.2 Hepatitis Drugs Market Drivers
8.3 Hepatitis Drugs Market Challenges
8.4 Hepatitis Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
F.Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline PLC
Johnson & Johnson
Merck
Novartis
Vertex Pharmaceuticals
AbbVie
Achillion Pharmaceuticals
Bristol–Myers Squibb
List of Tables
 Table 1. Global Hepatitis Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Hepatitis Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Hepatitis Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Hepatitis Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Hepatitis Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Hepatitis Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Hepatitis Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Hepatitis Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Hepatitis Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Hepatitis Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Hepatitis Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Hepatitis Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Hepatitis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Hepatitis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Hepatitis Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Hepatitis Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Hepatitis Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Hepatitis Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Hepatitis Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Hepatitis Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Hepatitis Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Hepatitis Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Hepatitis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Hepatitis Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Hepatitis Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Hepatitis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Hepatitis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Hepatitis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Hepatitis Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Hepatitis Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Hepatitis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Hepatitis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Hepatitis Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Hepatitis Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Hepatitis Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Hepatitis Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Hepatitis Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Hepatitis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Hepatitis Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Hepatitis Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Hepatitis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Hepatitis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Hepatitis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Hepatitis Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Hepatitis Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Hepatitis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Hepatitis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Hepatitis Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Hepatitis Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Hepatitis Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Hepatitis Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Hepatitis Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Hepatitis Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Hepatitis Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Hepatitis Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Hepatitis Drugs Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Hepatitis Drugs Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Hepatitis Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Hepatitis Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Hepatitis Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Hepatitis Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Hepatitis Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Hepatitis Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Hepatitis Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Hepatitis Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Hepatitis Drugs Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Hepatitis Drugs Price (USD/Unit) by Application (2026-2031)
 Table 70. F. Hoffmann-La Roche Company Information
 Table 71. F. Hoffmann-La Roche Description and Business Overview
 Table 72. F. Hoffmann-La Roche Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. F. Hoffmann-La Roche Hepatitis Drugs Product
 Table 74. F. Hoffmann-La Roche Recent Developments/Updates
 Table 75. Gilead Sciences Company Information
 Table 76. Gilead Sciences Description and Business Overview
 Table 77. Gilead Sciences Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Gilead Sciences Hepatitis Drugs Product
 Table 79. Gilead Sciences Recent Developments/Updates
 Table 80. GlaxoSmithKline Company Information
 Table 81. GlaxoSmithKline Description and Business Overview
 Table 82. GlaxoSmithKline Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. GlaxoSmithKline Hepatitis Drugs Product
 Table 84. GlaxoSmithKline Recent Developments/Updates
 Table 85. Johnson & Johnson Company Information
 Table 86. Johnson & Johnson Description and Business Overview
 Table 87. Johnson & Johnson Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Johnson & Johnson Hepatitis Drugs Product
 Table 89. Johnson & Johnson Recent Developments/Updates
 Table 90. Merck Company Information
 Table 91. Merck Description and Business Overview
 Table 92. Merck Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Merck Hepatitis Drugs Product
 Table 94. Merck Recent Developments/Updates
 Table 95. Novartis Company Information
 Table 96. Novartis Description and Business Overview
 Table 97. Novartis Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Novartis Hepatitis Drugs Product
 Table 99. Novartis Recent Developments/Updates
 Table 100. Vertex Pharmaceuticals Company Information
 Table 101. Vertex Pharmaceuticals Description and Business Overview
 Table 102. Vertex Pharmaceuticals Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Vertex Pharmaceuticals Hepatitis Drugs Product
 Table 104. Vertex Pharmaceuticals Recent Developments/Updates
 Table 105. Abbvie Company Information
 Table 106. Abbvie Description and Business Overview
 Table 107. Abbvie Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Abbvie Hepatitis Drugs Product
 Table 109. Abbvie Recent Developments/Updates
 Table 110. Achillion Pharmaceuticals Company Information
 Table 111. Achillion Pharmaceuticals Description and Business Overview
 Table 112. Achillion Pharmaceuticals Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Achillion Pharmaceuticals Hepatitis Drugs Product
 Table 114. Achillion Pharmaceuticals Recent Developments/Updates
 Table 115. Bristol-Myers Squibb Company Information
 Table 116. Bristol-Myers Squibb Description and Business Overview
 Table 117. Bristol-Myers Squibb Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Bristol-Myers Squibb Hepatitis Drugs Product
 Table 119. Bristol-Myers Squibb Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Hepatitis Drugs Distributors List
 Table 123. Hepatitis Drugs Customers List
 Table 124. Hepatitis Drugs Market Trends
 Table 125. Hepatitis Drugs Market Drivers
 Table 126. Hepatitis Drugs Market Challenges
 Table 127. Hepatitis Drugs Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Hepatitis Drugs
 Figure 2. Global Hepatitis Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Hepatitis Drugs Market Share by Type: 2024 & 2031
 Figure 4. VEMLIDY Product Picture
 Figure 5. EPCLUSA Product Picture
 Figure 6. SOVALDI Product Picture
 Figure 7. INCIVEK Product Picture
 Figure 8. OLYSIO Product Picture
 Figure 9. VICTRELIS Product Picture
 Figure 10. VIREAD Product Picture
 Figure 11. HEPSERA Product Picture
 Figure 12. BARACLUDE Product Picture
 Figure 13. Global Hepatitis Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 14. Global Hepatitis Drugs Market Share by Application: 2024 & 2031
 Figure 15. Hepatitis A
 Figure 16. Hepatitis B
 Figure 17. Hepatitis C
 Figure 18. Hepatitis D
 Figure 19. Hepatitis E
 Figure 20. Global Hepatitis Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 21. Global Hepatitis Drugs Market Size (2020-2031) & (US$ Million)
 Figure 22. Global Hepatitis Drugs Sales (2020-2031) & (K Units)
 Figure 23. Global Hepatitis Drugs Average Price (USD/Unit) & (2020-2031)
 Figure 24. Hepatitis Drugs Report Years Considered
 Figure 25. Hepatitis Drugs Sales Share by Manufacturers in 2024
 Figure 26. Global Hepatitis Drugs Revenue Share by Manufacturers in 2024
 Figure 27. Global 5 and 10 Largest Hepatitis Drugs Players: Market Share by Revenue in Hepatitis Drugs in 2024
 Figure 28. Hepatitis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 29. Global Hepatitis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 30. North America Hepatitis Drugs Sales Market Share by Country (2020-2031)
 Figure 31. North America Hepatitis Drugs Revenue Market Share by Country (2020-2031)
 Figure 32. U.S. Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Canada Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Europe Hepatitis Drugs Sales Market Share by Country (2020-2031)
 Figure 35. Europe Hepatitis Drugs Revenue Market Share by Country (2020-2031)
 Figure 36. Germany Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. France Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. U.K. Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Italy Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Russia Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Asia Pacific Hepatitis Drugs Sales Market Share by Region (2020-2031)
 Figure 42. Asia Pacific Hepatitis Drugs Revenue Market Share by Region (2020-2031)
 Figure 43. China Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Japan Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. South Korea Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. India Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Australia Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Taiwan Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Indonesia Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Thailand Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Malaysia Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Philippines Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Latin America Hepatitis Drugs Sales Market Share by Country (2020-2031)
 Figure 54. Latin America Hepatitis Drugs Revenue Market Share by Country (2020-2031)
 Figure 55. Mexico Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Brazil Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Argentina Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Middle East and Africa Hepatitis Drugs Sales Market Share by Country (2020-2031)
 Figure 59. Middle East and Africa Hepatitis Drugs Revenue Market Share by Country (2020-2031)
 Figure 60. Turkey Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 61. Saudi Arabia Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 62. U.A.E Hepatitis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 63. Global Sales Market Share of Hepatitis Drugs by Type (2020-2031)
 Figure 64. Global Revenue Market Share of Hepatitis Drugs by Type (2020-2031)
 Figure 65. Global Hepatitis Drugs Price (USD/Unit) by Type (2020-2031)
 Figure 66. Global Sales Market Share of Hepatitis Drugs by Application (2020-2031)
 Figure 67. Global Revenue Market Share of Hepatitis Drugs by Application (2020-2031)
 Figure 68. Global Hepatitis Drugs Price (USD/Unit) by Application (2020-2031)
 Figure 69. Hepatitis Drugs Value Chain
 Figure 70. Channels of Distribution (Direct Vs Distribution)
 Figure 71. Bottom-up and Top-down Approaches for This Report
 Figure 72. Data Triangulation
 Figure 73. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Feline Infectious Peritonitis (FIP) Antivirals Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4U20267
Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Global Anticoccidial Solutions Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-16R16865
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Bacterial Enteric Disease Testing Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-3F17301
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Whooping Cough Vaccination Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-4B20221
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions